Skip to main content
Top
Gepubliceerd in: Quality of Life Research 2/2016

15-08-2015 | Commentary

International Society for Quality of Life Research commentary on the draft European Medicines Agency reflection paper on the use of patient-reported outcome (PRO) measures in oncology studies

Auteurs: Derek Kyte, Bryce B. Reeve, Fabio Efficace, Kirstie Haywood, Rebecca Mercieca-Bebber, Madeleine T. King, Josephine M. Norquist, William R. Lenderking, Claire Snyder, Lena Ring, Galina Velikova, Melanie Calvert

Gepubliceerd in: Quality of Life Research | Uitgave 2/2016

Log in om toegang te krijgen
share
DELEN

Deel dit onderdeel of sectie (kopieer de link)

  • Optie A:
    Klik op de rechtermuisknop op de link en selecteer de optie “linkadres kopiëren”
  • Optie B:
    Deel de link per e-mail

Abstract

In 2014, the European Medicines Agency (EMA) released for comment a draft reflection paper on the use of patient-reported outcome (PRO) measures in oncology studies. A twelve-member International Society for Quality of Life Research (ISOQOL) taskforce was convened to coordinate the ISOQOL response. Twenty-one ISOQOL members provided detailed comments and suggestions on the paper: 81 % from academia and 19 % from industry. Taskforce members consolidated and further refined these comments and shared the recommendations with the wider ISOQOL membership. A final response was submitted to the EMA in November 2014. The impending publication of the EMA reflection paper presents a valuable opportunity for ISOQOL to comment on the current direction of EMA PRO guidance and strategy. The EMA paper, although focused on cancer, could serve as a model for using PROs in other conditions, as it provides a useful update surrounding some of the design issues common to all trial research including PRO endpoints. However, we believe there are a number of additional areas in need of greater consideration. The purpose of this commentary is therefore to highlight the strengths of this timely and potentially useful document, but also to outline areas that may warrant further discussion.
Literatuur
1.
go back to reference EMA. (2014). Reflection Paper on the use of patient reported outcome (PRO) measures in oncology studies [Draft]. European Medicines Agency, Oncology Working Party; Doc. Ref. EMA/CHMP/292464/2014. EMA. (2014). Reflection Paper on the use of patient reported outcome (PRO) measures in oncology studies [Draft]. European Medicines Agency, Oncology Working Party; Doc. Ref. EMA/CHMP/292464/2014.
2.
go back to reference EMA. (2005). Reflection paper on the regulatory guidance for the use of health-related quality of life (HRQL) measures in the evaluation of medicinal products. European Medicines Agency, Committee for medicinal products for human use (CHMP); Doc. Ref. EMEA/CHMP/EWP/139391/2004. EMA. (2005). Reflection paper on the regulatory guidance for the use of health-related quality of life (HRQL) measures in the evaluation of medicinal products. European Medicines Agency, Committee for medicinal products for human use (CHMP); Doc. Ref. EMEA/CHMP/EWP/139391/2004.
4.
go back to reference Kyte, D., Ives, J., Draper, H., Keeley, T., & Calvert, M. (2013). Inconsistencies in quality of life data collection in clinical trials: A potential source of bias? Interviews with research nurses and trialists. PLoS One, 8(10), e76625.PubMedCentralCrossRefPubMed Kyte, D., Ives, J., Draper, H., Keeley, T., & Calvert, M. (2013). Inconsistencies in quality of life data collection in clinical trials: A potential source of bias? Interviews with research nurses and trialists. PLoS One, 8(10), e76625.PubMedCentralCrossRefPubMed
5.
go back to reference Kyte, D. G., Draper, H., Ives, J., Liles, C., Gheorghe, A., & Calvert, M. (2013). Patient reported outcomes (PROs) in clinical trials: is ‘in-trial’ guidance lacking? A systematic review. PLoS One, 8(4), e60684.PubMedCentralCrossRefPubMed Kyte, D. G., Draper, H., Ives, J., Liles, C., Gheorghe, A., & Calvert, M. (2013). Patient reported outcomes (PROs) in clinical trials: is ‘in-trial’ guidance lacking? A systematic review. PLoS One, 8(4), e60684.PubMedCentralCrossRefPubMed
6.
go back to reference Basch, E. M., Abernethy, A., Mullins, C. D., Tiglao, M. R., & Tunis, S. R. (2011). Development of a guidance for including patient-reported outcomes (PROS) in post-approval clinical trials of oncology drugs for comparative effectiveness research (CER). Value in Health, 14(3), A10.CrossRef Basch, E. M., Abernethy, A., Mullins, C. D., Tiglao, M. R., & Tunis, S. R. (2011). Development of a guidance for including patient-reported outcomes (PROS) in post-approval clinical trials of oncology drugs for comparative effectiveness research (CER). Value in Health, 14(3), A10.CrossRef
8.
go back to reference Reeve, B. B., Mitchell, S. A., Dueck, A. C., Basch, E., Cella, D., & Reilly, C. M. et al. (2014). Recommended patient-reported core set of symptoms to measure in adult cancer treatment trials. Journal of the National Cancer Institute, 106(7), dju129. Reeve, B. B., Mitchell, S. A., Dueck, A. C., Basch, E., Cella, D., & Reilly, C. M. et al. (2014). Recommended patient-reported core set of symptoms to measure in adult cancer treatment trials. Journal of the National Cancer Institute, 106(7), dju129.
9.
go back to reference Brundage, M., Bass, B., Davidson, J., Queenan, J., Bezjak, A., Ringash, J., et al. (2011). Patterns of reporting health-related quality of life outcomes in randomized clinical trials: Implications for clinicians and quality of life researchers. Quality of Life Research, 20, 653–664.CrossRefPubMed Brundage, M., Bass, B., Davidson, J., Queenan, J., Bezjak, A., Ringash, J., et al. (2011). Patterns of reporting health-related quality of life outcomes in randomized clinical trials: Implications for clinicians and quality of life researchers. Quality of Life Research, 20, 653–664.CrossRefPubMed
10.
go back to reference Calvert, M., Blazeby, J., Altman, D. G., Revicki, D., Moher, D., & Brundage, M. (2013). Reporting of patient reported outcomes in randomised trials: The CONSORT PRO extension. JAMA, 309(8), 814–822.CrossRefPubMed Calvert, M., Blazeby, J., Altman, D. G., Revicki, D., Moher, D., & Brundage, M. (2013). Reporting of patient reported outcomes in randomised trials: The CONSORT PRO extension. JAMA, 309(8), 814–822.CrossRefPubMed
12.
go back to reference Taphoorn, M. J., Stupp, R., Coens, C., Osoba, D., Kortmann, R., van den Bent, M. J., et al. (2005). Health-related quality of life in patients with glioblastoma: A randomised controlled trial. The lancet Oncology, 6(12), 937–944.CrossRefPubMed Taphoorn, M. J., Stupp, R., Coens, C., Osoba, D., Kortmann, R., van den Bent, M. J., et al. (2005). Health-related quality of life in patients with glioblastoma: A randomised controlled trial. The lancet Oncology, 6(12), 937–944.CrossRefPubMed
13.
go back to reference Marin, D., Bazeos, A., Mahon, F.-X., Eliasson, L., Milojkovic, D., Bua, M., et al. (2010). Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. Journal of Clinical Oncology, 28(14), 2381–2388.CrossRefPubMed Marin, D., Bazeos, A., Mahon, F.-X., Eliasson, L., Milojkovic, D., Bua, M., et al. (2010). Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. Journal of Clinical Oncology, 28(14), 2381–2388.CrossRefPubMed
14.
go back to reference Brett, J., Staniszewska, S., Mockford, C., Herron‐Marx, S., Hughes, J., & Tysall, C. et al. (2014). Mapping the impact of patient and public involvement on health and social care research: A systematic review. Health Expectations, 17(5), 637–650.CrossRef Brett, J., Staniszewska, S., Mockford, C., Herron‐Marx, S., Hughes, J., & Tysall, C. et al. (2014). Mapping the impact of patient and public involvement on health and social care research: A systematic review. Health Expectations, 17(5), 637–650.CrossRef
15.
go back to reference Gradinger, F., Britten, N., Wyatt, K., Froggatt, K., Gibson, A., & Jacoby, A. et al. (2013). Values associated with public involvement in health and social care research: A narrative review. Health Expectations. doi:10.1111/hex.12158. Gradinger, F., Britten, N., Wyatt, K., Froggatt, K., Gibson, A., & Jacoby, A. et al. (2013). Values associated with public involvement in health and social care research: A narrative review. Health Expectations. doi:10.​1111/​hex.​12158.
16.
go back to reference de Wit, M. P., Abma, T. A., Koelewijn-van Loon, M. S., Collins, S., & Kirwan, J. (2014). What has been the effect on trial outcome assessments of a decade of patient participation in OMERACT? The Journal of Rheumatology, 41(1), 177–184.CrossRefPubMed de Wit, M. P., Abma, T. A., Koelewijn-van Loon, M. S., Collins, S., & Kirwan, J. (2014). What has been the effect on trial outcome assessments of a decade of patient participation in OMERACT? The Journal of Rheumatology, 41(1), 177–184.CrossRefPubMed
17.
go back to reference Staniszewska, S., Haywood, K. L., Brett, J., & Tutton, L. (2012). Patient and public involvement in patient-reported outcome measures. The Patient-Patient-Centered Outcomes Research, 5(2), 79–87.CrossRefPubMed Staniszewska, S., Haywood, K. L., Brett, J., & Tutton, L. (2012). Patient and public involvement in patient-reported outcome measures. The Patient-Patient-Centered Outcomes Research, 5(2), 79–87.CrossRefPubMed
18.
go back to reference Kirwan, J. R., Minnock, P., Adebajo, A., Bresnihan, B., Choy, E., De Wit, M., et al. (2007). Patient perspective: Fatigue as a recommended patient centered outcome measure in rheumatoid arthritis. The Journal of Rheumatology, 34(5), 1174–1177.PubMed Kirwan, J. R., Minnock, P., Adebajo, A., Bresnihan, B., Choy, E., De Wit, M., et al. (2007). Patient perspective: Fatigue as a recommended patient centered outcome measure in rheumatoid arthritis. The Journal of Rheumatology, 34(5), 1174–1177.PubMed
19.
go back to reference Nicklin, J., Cramp, F., Kirwan, J., Urban, M., & Hewlett, S. (2010). Collaboration with patients in the design of patient-reported outcome measures: Capturing the experience of fatigue in rheumatoid arthritis. Arthritis Care & Research, 62(11), 1552–1558.CrossRef Nicklin, J., Cramp, F., Kirwan, J., Urban, M., & Hewlett, S. (2010). Collaboration with patients in the design of patient-reported outcome measures: Capturing the experience of fatigue in rheumatoid arthritis. Arthritis Care & Research, 62(11), 1552–1558.CrossRef
Metagegevens
Titel
International Society for Quality of Life Research commentary on the draft European Medicines Agency reflection paper on the use of patient-reported outcome (PRO) measures in oncology studies
Auteurs
Derek Kyte
Bryce B. Reeve
Fabio Efficace
Kirstie Haywood
Rebecca Mercieca-Bebber
Madeleine T. King
Josephine M. Norquist
William R. Lenderking
Claire Snyder
Lena Ring
Galina Velikova
Melanie Calvert
Publicatiedatum
15-08-2015
Uitgeverij
Springer International Publishing
Gepubliceerd in
Quality of Life Research / Uitgave 2/2016
Print ISSN: 0962-9343
Elektronisch ISSN: 1573-2649
DOI
https://doi.org/10.1007/s11136-015-1099-z

Andere artikelen Uitgave 2/2016

Quality of Life Research 2/2016 Naar de uitgave